{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:38:15Z","timestamp":1783960695945,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018554","name":"Science and Technology Program of Gansu Province","doi-asserted-by":"publisher","award":["23ZDFA003"],"award-info":[{"award-number":["23ZDFA003"]}],"id":[{"id":"10.13039\/501100018554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["lzujbky-2022-sp09"],"award-info":[{"award-number":["lzujbky-2022-sp09"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017619","name":"Northwest Minzu University","doi-asserted-by":"publisher","award":["31920240080"],"award-info":[{"award-number":["31920240080"]}],"id":[{"id":"10.13039\/501100017619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bmc.2025.118379","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:57:59Z","timestamp":1757001479000},"page":"118379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Identification and biological evaluation of novel indole-2-one derivatives as BRD4-BD2 inhibitors"],"prefix":"10.1016","volume":"130","author":[{"given":"Chang-Jiang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Hang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Juan","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Wu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118379_bb0005","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents, brit","volume":"124","author":"Shorstova","year":"2021","journal-title":"J Cancer"},{"key":"10.1016\/j.bmc.2025.118379_bb0010","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","article-title":"Bromodomains: a new target class for drug development","volume":"18","author":"Cochran","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2025.118379_bb0015","article-title":"The BET family in immunity and disease","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Tar"},{"key":"10.1016\/j.bmc.2025.118379_bb0020","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/s41594-019-0309-8","article-title":"Bromodomain biology and drug discovery","volume":"26","author":"Zaware","year":"2019","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bmc.2025.118379_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112426","article-title":"Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery","volume":"200","author":"Liang","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118379_bb0030","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1021\/acs.jmedchem.6b01761","article-title":"Drug discovery targeting Bromodomain-containing protein 4","volume":"60","author":"Liu","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118379_bb0035","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1126\/science.abb5060","article-title":"Next-generation epigenetic inhibitors","volume":"368","author":"Filippakopoulos","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bmc.2025.118379_bb0040","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1021\/acs.jmedchem.1c01835","article-title":"Targeting Bromodomain-selective inhibitors of BET proteins in drug discovery and development","volume":"65","author":"Chen","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118379_bb0045","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1126\/science.aaz8455","article-title":"Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation","volume":"368","author":"Gilan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bmc.2025.118379_bb0050","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/acs.jmedchem.0c01487","article-title":"Targeting Bromodomain and Extraterminal proteins for drug discovery: from current Progress to technological development","volume":"64","author":"Tang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118379_bb0055","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.aat6664","article-title":"TRANSCRIPTION BRD4 and MYC-clarifying regulatory specificity","volume":"360","author":"Sabo","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.bmc.2025.118379_bb0060","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118379_bb0065","doi-asserted-by":"crossref","first-page":"8369","DOI":"10.1021\/acs.jmedchem.7b00746","article-title":"Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075\/Mivebresib), a potent and orally available Bromodomain and Extraterminal domain (BET) family Bromodomain inhibitor","volume":"60","author":"McDaniel","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118379_bb0070","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-12-3292","article-title":"PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains","volume":"73","author":"Picaud","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118379_bb0075","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","article-title":"Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer","volume":"578","author":"Faivre","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118379_bb0080","doi-asserted-by":"crossref","first-page":"19754","DOI":"10.1073\/pnas.1310658110","article-title":"RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain","volume":"110","author":"Picaud","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2025.118379_bb0085","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bbrc.2016.06.021","article-title":"RVX-297-a novel BD2 selective inhibitor of BET bromodomains","volume":"477","author":"Kharenko","year":"2016","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.bmc.2025.118379_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111633","article-title":"Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins","volume":"182","author":"Chen","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118379_bb0095","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1021\/acs.jmedchem.0c00628","article-title":"Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain inhibitor with selectivity for the second Bromodomain","volume":"63","author":"Sheppard","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118379_bb0100","doi-asserted-by":"crossref","first-page":"9070","DOI":"10.1021\/acs.jmedchem.0c00605","article-title":"Design and synthesis of a highly selective and in vivo-capable inhibitor of the second Bromodomain of the Bromodomain and extra terminal domain family of proteins","volume":"63","author":"Preston","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118379_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083190","article-title":"RVX-208, an inducer of ApoA-I in humans, is a BET Bromodomain antagonist","volume":"8","author":"McLure","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2025.118379_bb0110","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1517\/13543784.2015.1083010","article-title":"An evaluation of RVX-208 for the treatment of atherosclerosis","volume":"24","author":"Nikolic","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bmc.2025.118379_bb0115","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jacc.2010.11.015","article-title":"Efficacy and safety of a novel Oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial","volume":"57","author":"Nicholls","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.bmc.2025.118379_bb0120","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1021\/acs.jmedchem.2c00100","article-title":"Structure-based discovery and optimization of Furo[3,2-c]pyridin-4(5H)-one derivatives as potent and second Bromodomain (BD2)-selective Bromo and extra terminal domain (BET) inhibitors","volume":"65","author":"Li","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118379_bb0125","doi-asserted-by":"crossref","first-page":"10824","DOI":"10.1021\/acs.jmedchem.3c01028","article-title":"Discovery of a Bromodomain and extra terminal domain (BET) inhibitor with the selectivity for the second Bromodomain (BD2) and the capacity for the treatment of inflammatory diseases","volume":"66","author":"Wang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118379_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112780","article-title":"Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors","volume":"208","author":"Xu","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118379_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117752","article-title":"Discovery of indole-2-one derivatives as BRD4 (BD1) selective inhibitors","volume":"106","author":"Qiao","year":"2024","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118379_bb0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/excr.1999.4686","article-title":"Function of the c-Myc oncogenic transcription factor","volume":"253","author":"Dang","year":"1999","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.bmc.2025.118379_bb0145","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118379_bb0150","doi-asserted-by":"crossref","first-page":"8642","DOI":"10.1021\/acs.jmedchem.9b01094","article-title":"Structure-based discovery and development of a series of potent and selective Bromodomain and extra-terminal protein inhibitors","volume":"62","author":"Hu","year":"2019","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625003207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625003207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:58:22Z","timestamp":1762347502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625003207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"alternative-id":["S0968089625003207"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118379","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and biological evaluation of novel indole-2-one derivatives as BRD4-BD2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118379"}}